the Real World Study of Orelabrutinib in the Treatment of CLL/SLL

Shandong University

Status: Not yet enrolling

Conditions: CLL/SLL

Study type: Observational

Funder types: Other

Identifiers

NCT05975164

Orelabrutinib in real world

Details and patient eligibility

About

This is a Multicenter, Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Full description

Orelabrutinib is a novel BTK inhibitor with high selectivity and has been approved in China for relapsed/refractory CLL/SLL,, The purpose of this study is to describe the effectiveness and safety of orelabrutinib of chronic lymphocytic leukemia (CLL) in real world.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18 years old
2. Patients with a definite diagnosis of CLL/SLL
3. Prior or current use of orelabrutinib for ≥3 months
4. At least one follow-up was recorded during orelabrutinib treatment

Exclusion criteria

1.Patients who received orelabrutinib in a prospective clinical trial